Xtant Medical Holdings Inc  

(Public, NYSEMKT:XTNT)   Watch this stock  
Find more results for AMEX:XTNT
0.430
-0.060 (-12.24%)
After Hours: 0.485 +0.055 (12.79%)
Jan 20, 4:27PM EST  
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 0.42 - 0.51
52 week 0.42 - 3.75
Open 0.51
Vol / Avg. 967,149.00/419,587.00
Mkt cap 7.24M
P/E     -
Div/yield     -
EPS -0.27
Shares 18.09M
Beta 0.88
Inst. own 12%
Mar 13, 2017
Q4 2016 Xtant Medical Holdings Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Nov 8, 2016
Q3 2016 Xtant Medical Holdings Inc Earnings Call
Nov 7, 2016
Q3 2016 Xtant Medical Holdings Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -21.21% -3.66%
Operating margin -8.24% -20.35%
EBITD margin - -7.35%
Return on average assets -13.85% -2.57%
Return on average equity - -394.77%
Employees 243 -
CDP Score - -

Address

664 Cruiser Ln
BELGRADE, MT 59714-9719
United States - Map
+1-406-3880480 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Xtant Medical Holdings, Inc., formerly Bacterin International Holdings, Inc., develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. The Company operates through the development, manufacture and marketing of regenerative medical products and devices segment. Its biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, BacFast HD, OsteoSTX, hMatrix and 3Demin products, as well as other allografts. Its products serve the needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, foot and ankle surgeries. It also processes and distributes sports allografts, milled spinal allografts and allografts for multi-disciplinary applications.

Officers and directors

Kent L. Swanson Independent Chairman of the Board
Age: 70
Bio & Compensation  - Reuters
Carl D. O'Connell President
Age: 53
Bio & Compensation  - Reuters
Daniel S. Goldberger Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
John P. Gandolfo Chief Financial Officer
Age: 54
Bio & Compensation  - Reuters
Darrel Lee Holmes Chief Operating Officer
Age: 62
Bio & Compensation  - Reuters
Gregory Juda Ph.D. Chief Scientific Officer
Age: 39
Bio & Compensation  - Reuters
David Louis Kirschman M.D. Director
Age: 55
Bio & Compensation  - Reuters
Paul R. Buckman Independent Director
Age: 60
Bio & Compensation  - Reuters
John Deedrick Independent Director
Age: 52
Bio & Compensation  - Reuters
Michael A. Lopach CPA Independent Director
Age: 66
Bio & Compensation  - Reuters